- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Appili Therapeutics Inc.: Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results | 834 | GlobeNewswire (Europe) | LIKMEZ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL re-launched and commercial sales ongoing Five U.S. government proposals submitted, totalling up to US$125 million HALIFAX, Nova Scotia... ► Artikel lesen | |
| 30.05. | Stocks in Play: Appili Therapeutics Inc. | 1 | Baystreet.ca | ||
| 30.05. | Appili Therapeutics Inc.: Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc. | 200 | GlobeNewswire (Europe) | NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, May 30, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink:... ► Artikel lesen | |
| 20.05. | Appili Therapeutics Inc: Appili to receive termination fee from Aditxt | 1 | Stockwatch | ||
| 19.05. | Aditxt to terminate arrangement agreement with Appili Therapeutics | 1 | Seeking Alpha | ||
| 19.05. | Appili Therapeutics Inc.: Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc. | 207 | GlobeNewswire (Europe) | NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, May 19, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink:... ► Artikel lesen | |
| 01.05. | Appili Therapeutics Inc.: Appili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia | 1 | GlobeNewswire (USA) | ||
| 28.04. | Appili Therapeutics Inc: Appili Therapeutics granted patents in U.S., Mexico | 1 | Stockwatch | ||
| APPILI THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 28.04. | Stocks in Play: Appili Therapeutics Inc. | - | Baystreet.ca | ||
| 28.04. | Appili Therapeutics Inc.: Appili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZ | 135 | GlobeNewswire (Europe) | New patents provide additional composition of matter and methods of use claims, strengthening the protection for liquid oral taste-masked reformulation, LIKMEZ New subject matter listed in the U.S.... ► Artikel lesen | |
| 02.04. | Appili Therapeutics Inc: Appili president to join Aditxt's April 4 update | 2 | Stockwatch | ||
| 02.04. | Appili Therapeutics Inc.: Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025 | 2 | GlobeNewswire (USA) | ||
| 18.03. | Appili Therapeutics Inc: Appili Therapeutics submits U.S. funding applications | 1 | Stockwatch | ||
| 18.03. | Stocks in Play: Appili Therapeutics Inc. | 1 | Baystreet.ca | ||
| 18.03. | Appili Therapeutics Inc.: Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update | 182 | GlobeNewswire (Europe) | Four new funding proposals, totalling US$117.5 million, have been submitted for reviewModifications received to U.S. Air Force Academy Cooperative AgreementOutside date for going-private transaction... ► Artikel lesen | |
| 14.02. | Appili Therapeutics Inc.: Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025 | 682 | GlobeNewswire (Europe) | Received overwhelming shareholder support in favour of take-private transaction with Aditxt Advanced key pipeline programs, engaged regulatory authorities on ATI-1801 and preparing ATI-1701 for an... ► Artikel lesen | |
| 19.11.24 | Appili Therapeutics Inc.: Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc. | 289 | GlobeNewswire (Europe) | NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Court's approval allows transaction with Aditxt to proceed, subject to other closing conditions HALIFAX... ► Artikel lesen | |
| 14.11.24 | Appili Therapeutics Inc.: Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025 | 159 | GlobeNewswire (Europe) | Overwhelming shareholder support in favour of take-private transaction with Aditxt Studies presented at IDWeek 2024 demonstrate ATI-1701 provides full protection against lethal tularemia in animal... ► Artikel lesen | |
| 07.11.24 | Appili Therapeutics Inc.: Appili Therapeutics Announces Results of Special Meeting of Shareholders | 144 | GlobeNewswire (Europe) | NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink:... ► Artikel lesen | |
| 31.10.24 | Appili Therapeutics Inc.: Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission | 187 | GlobeNewswire (Europe) | Demonstrated safety and efficacy across multiple Phase 2 and Phase 3 studies Appili provides update on Aditxt transaction and encourages shareholders to vote their shares as soon as possible for... ► Artikel lesen |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABBVIE | 157,00 | -0,38 % | Aktienmarkt: Kurs der Aktie von AbbVie im Plus (159,9573 €) | Die Aktie von AbbVie notiert heute ein wenig fester. Das Papier kostete zuletzt 185,88 US-Dollar. Der Anteilsschein von AbbVie verzeichnet zur Stunde einen Preisanstieg von 1,15 Prozent. Er hat sich... ► Artikel lesen | |
| INNOCAN PHARMA | 0,144 | +1,77 % | InnoCan Pharma: Mega-News im Anmarsch? | ||
| TAAT GLOBAL ALTERNATIVES | 0,136 | -100,00 % | CSE Bulletin: Suspensions - Blender Bites Limited, TAAT Global Alternatives Inc. | Toronto, Ontario--(Newsfile Corp. - Le 16 mai/May 2025) - Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as... ► Artikel lesen | |
| DIGICANN VENTURES | 0,004 | 0,00 % | Digicann Ventures Inc.: Digicann Ventures Provides Update Regarding Proposed RTO Transaction | / Not for distribution to U.S. news wire services or for dissemination in the United States / VANCOUVER, British Columbia, April 22, 2025 (GLOBE NEWSWIRE) -- Digicann Ventures Ltd. ("Digicann" or... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 30,200 | -1,31 % | Tonix Pharmaceuticals to be added to Russell 3000, Russell 2000 indexes | ||
| AEQUUS PHARMACEUTICALS | 0,005 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 13.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 13.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 13.05.2025ISIN NameUS2310828015 CUMULUS... ► Artikel lesen | |
| SHANGHAI PHARMACEUTICALS | 1,260 | -0,79 % | SH PHARMA (02607): FINAL DIVIDENDS FOR THE YEAR ENDED 31 DECEMBER 2024 (UPDATED) | ||
| CIPHER PHARMACEUTICALS | 7,750 | 0,00 % | Cipher Pharmaceuticals Announces Results of Annual and Special Meeting of Shareholders | ||
| BAYER | 26,170 | +2,49 % | DZ BANK stuft BAYER AG auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat die Aktien von Bayer bei einem fairen Wert von 36 Euro auf "Kaufen" belassen. Der Agrarchemie- und Pharmakonzern sei besser als erwartet ins Jahr gestartet... ► Artikel lesen | |
| MERCK KGAA | 109,55 | -0,41 % | UBS stuft MERCK KGAA auf 'Buy' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Merck KGaA mit Blick auf das dritte Quartal 2025 auf "Buy" belassen. In den Fokus könnten Nachrichten zum Medikament Varegacestat... ► Artikel lesen | |
| NOVO NORDISK | 57,97 | -1,24 % | Depot Verdoppler mit Künstlicher Intelligenz: Novo Nordisk, PanGenomic Health und Pfizer zünden 2025 den Profit-Turbo | Lauf BlackRock Health Sciences steht der globale Gesundheitssektor 2025 vor einem beispiellosen Aufschwung. Nach Jahren der Volatilität durch die Pandemie soll die Branche jetzt die höchsten Gewinnzuwächse... ► Artikel lesen | |
| METSERA | 28,450 | 0,00 % | Metsera, Inc.: Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i | Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination Well-tolerated... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 3,310 | 0,00 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit | ||
| EYENOVIA | 10,260 | 0,00 % | Eyenovia erweitert HYPE-Token-Bestände um mehr als 265.000 | ||
| GSK | 16,290 | -0,28 % | JPMORGAN stuft GSK auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat GSK den Stempel "Negative Catalyst Watch" aufgedrückt. Das Risiko eines negativen Votums der US-Gesundheitsbehörde FDA für das Medikament Blenrep... ► Artikel lesen |
Das Unternehmen APPILI THERAPEUTICS INC kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu APPILI THERAPEUTICS INC finden Sie auf Wallstreet Online.